Welcome!

Microsoft Cloud Authors: Pat Romanski, Liz McMillan, Lori MacVittie, Elizabeth White, Yeshim Deniz

News Feed Item

Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

 

DUBLIN, Apr. 03, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/zvzsf4/antibodydrug) has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" report to their offering.

(Logo:http://photos.prnewswire.com/prnh/20130307/600769)

The report entitled 'Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis' is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between pharma, biotech and the service industry serve to identify those technologies of interest for stakeholders in the ADC industry.

The report was built from the bottom-up by first elaborating Company Profiles from information retrieved from proprietary antibody-drug conjugate database, scientific literature and abstracts, company press releases, company presentations, financial disclosures, clinical trials databases and company websites. A structured analysis was performed for the ADC pipeline, for stakeholders of the ADC industry, for state-of-the art and emerging ADC technologies, for the ADC manufacturing and service industry, and business activities. The report identifies trends for those ADC technologies (target, antibody, drug, linker and conjugation systems) which are of interest for the industry.

The report includes in the Addendum a tabulated Competitor Analysis and lists all relevant business transactions of the last two to three years.

Spefically, the ADC pipeline analysis describes preclinical, non-clinical and clinical ADC projects and R&D programs. It evaluates the ADC targets in relation to drug and linker systems, and also investigates the clinical success and reasons for failures of antibody-drug conjugates.

The stakeholder analysis compares companies with their peers in the respective group of development, technology and manufacturing companies and further categorizes them within the respective group to find out their competitive situation.

The analysis pays special attention to the importance of target selection, to emerging trends of new targeting moieties beyond full-length, canonical antibodies, to the expansion of the use of ADCs in non-cancer indications, to the opportunities arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs.

Crticial issues of ADCs, such as therapeutic window, druggable targets, manufacturing and financing are addressed and opportunities outlined.


Key Topics Covered:

1 Executive Summary

2 Introduction and Overview of the Report

3 Antibody-Drug Conjugates: Pipeline Description and Analysis

4 Stakeholders in Antibody-Drug Conjugates and Immunoconjugates

5 ADC Technologies

6 Business with Antibody-Drug Conjugates

7 ADC & Immunoconjugate Company Profiles

8 References

9 Tables


Companies Mentioned:

  • ACES Pharma
  • ADC Therapeutics
  • AbGenomics
  • AbbVie
  • Abbott Contract Manufacturing
  • Ablynx
  • Adcanced Proteome Therapeutics
  • Aeterna Zentaris
  • Affinicon
  • Albany Molecular Research Inc (AMRI)
  • Allozyne
  • Ambrx
  • Amgen
  • Amunix
  • Arrowhead Research
  • Astellas Pharma
  • AstraZeneca
  • Auven Therapeutics
  • BIND Therapeutics
  • BSP Pharmaceuticals
  • Baxter BioPharma Solutions
  • Bayer HealthCare Pharmaceuticals
  • Biotecnol
  • Biotest
  • Bristol-Myers Squibb
  • Carbogen Amcis
  • Catalent Biologics
  • Celgene
  • Celldex Therapeutics
  • Centrose
  • Coldstream Laboratories
  • Concortis Biosystems
  • CytomX
  • Daiichi Sankyo
  • Eli Lilly
  • Endo Pharmaceuticals
  • Esperance Pharmaceuticals
  • Evonik Industries
  • Fujifilm Diosynth Biotechnologies
  • Genmab
  • GlaxoSmithKline
  • Glykos
  • Goodwin Biotechnology
  • Helix Biopharma
  • Heraeus
  • Igenica
  • Immune Pharmaceuticals
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • Intellect Neurosciences
  • Janssen Research & Development
  • Lonza
  • Macrogenics
  • Meditope Biosciences
  • Menarini
  • Merck
  • Mersana Therapeutics
  • Molecular Partners
  • Nerviano Medical Sciences
  • Novartis
  • Novasep
  • Oncomatrix
  • Oxford BioTherapeutics
  • Pfizer
  • Philogen
  • Photobiotics
  • Phylogica
  • Pierre Fabre Group
  • Pierre Fabre Medicament Production
  • Piramal
  • Polytherics
  • Progenics Pharmaceuticals
  • Quanta Biodesign
  • Redwood Biodesign
  • Roche
  • Sanofi
  • Seattle Genetics
  • Serina Therapeutics
  • Shire
  • Sigma Aldrich SAFC
  • Sorrento Therapeutics
  • Spirogen
  • Stem CentRx
  • Sutro Biopharma
  • SynAffix
  • Synthon Biopharmaceuticals
  • TUBE Pharma
  • Takeda Pharmaceutical
  • The Chemistry Research Solution
  • University of California San Diego
  • Wilex (Heidelberg Pharma)
  • WuXi PharmaTech
  • Zhejiang Medicine
  • Zymeworks
  • f-star



For more information visit http://www.researchandmarkets.com/research/zvzsf4/antibodydrug


Media Contact: Laura Wood , +353-1-481-1716, [email protected]



More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
Bill Schmarzo, Tech Chair of "Big Data | Analytics" of upcoming CloudEXPO | DXWorldEXPO New York (November 12-13, 2018, New York City) today announced the outline and schedule of the track. "The track has been designed in experience/degree order," said Schmarzo. "So, that folks who attend the entire track can leave the conference with some of the skills necessary to get their work done when they get back to their offices. It actually ties back to some work that I'm doing at the University of ...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...